Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + camrelizumab
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Surufatinib + camrelizumab is a combination therapy comprising surufatinib, an oral small molecule multi-kinase inhibitor, and camrelizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Surufatinib uniquely targets VEGFR 1, 2, and 3, FGFR1, and CSF-1R. By inhibiting CSF-1R, surufatinib modulates the tumor microenvironment by reducing tumor-associated macrophages, which is hypothesized to synergize with camrelizumab's ability to restore T-cell mediated anti-tumor immunity. This combination is primarily being investigated in China for the treatment of advanced solid tumors, particularly biliary tract cancers such as gallbladder carcinoma and bile duct carcinoma, where it aims to overcome resistance to single-agent immunotherapy through dual anti-angiogenic and immunomodulatory mechanisms.
- Brand names
- AiRuiKa + Sulanda
- Other names
- Surufatinib plus Camrelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + camrelizumab.